HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Lupus erythematosus — Clinical Guidelines

Overview

Lupus erythematosus (LE) encompasses a spectrum of autoimmune connective tissue diseases characterized by immune complex formation and tissue inflammation, affecting primarily the skin but potentially involving multiple organs. 16

Diagnosis

Clinical Features: Rash patterns (e.g., discoid, hypertrophic), photosensitivity, oral ulcers. 3 8

Histopathology: Characteristic findings include interface dermatitis, mucin deposition, and follicular plugging. 1 8

Serological Tests: Antinuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA) antibodies, complement levels (C3, C4). 17

Imaging/Biopsy: Skin biopsy essential for definitive diagnosis, especially in cutaneous forms. 1 17

Management

First-Line Treatments:

- Topical Corticosteroids: For localized skin lesions. 5 - Antimalarials: Hydroxychloroquine (max dose 3.5-4.0 mg/kg/day) for systemic involvement and chronic cutaneous forms. 7

Adjunctive Treatments:

- Systemic Corticosteroids: For severe or systemic manifestations. 5 - Immunosuppressants: Azathioprine, mycophenolate mofetil for refractory cases. 5 - Avoidance of Triggering Agents: Discontinue causative medications (e.g., minocycline, carbamazepine). 2 14 18

Special Populations

Pediatrics: Discoid lupus erythematosus (DLE) presents in childhood with similar features but requires careful monitoring due to growth and development concerns. Mean age 8.9 years, F:M ratio 1.8. 3

Drug-Induced LE: Recognize and manage drug-induced lupus, particularly with antibiotics (minocycline, doxycycline) and other medications like topiramate and ethosuximide. 2 14 15

Comorbidities: Monitor for associated conditions like autoimmune hepatitis with minocycline use. 14

Key Recommendations

Biopsy for Definitive Diagnosis: Skin biopsy is essential for diagnosing cutaneous lupus erythematosus. (Evidence: Strong 1 17)

Use of Antimalarials: Hydroxychloroquine should be considered for chronic cutaneous lupus erythematosus, adhering to safe dosing guidelines. (Evidence: Moderate 7)

Discontinue Triggering Medications: Identify and discontinue medications known to induce lupus-like syndromes. (Evidence: Moderate 2 14 15)

Monitor Pediatric Patients: Closely monitor pediatric patients with DLE for disease progression and impact on growth. (Evidence: Expert opinion)

References

1 Luo SY, Wang QX, Zhou KY, Deng LJ, Fang S. Papulonodular mucinosis: a systematic review on clinicopathologic characteristics, course and treatment options. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2025. link 2 Kaya Akca U, Sener S, Batu ED, Balik Z, Basaran O, Bilginer Y et al.. Drug-induced lupus erythematosus in childhood: Case-based review. Lupus 2024. link 3 Hawat T, Ballouz S, Megarbane H, Haber R. Pediatric discoid lupus erythematosus: Short report. Dermatologic therapy 2022. link 4 Gorrepati PL, Smith GP. Assessing the quality of acne and rosacea treatment information on YouTube. Clinical and experimental dermatology 2022. link 5 Creadore A, Watchmaker J, Maymone MBC, Pappas L, Vashi NA, Lam C. Cosmetic treatment in patients with autoimmune connective tissue diseases: Best practices for patients with lupus erythematosus. Journal of the American Academy of Dermatology 2020. link 6 Holubar K, Fatovic-Ferencic S. Entities and eponyms: two each, and a painter--"175" years on. Skinmed 2012. link 7 Ochsendorf FR. Use of antimalarials in dermatology. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2010. link 8 Farley-Loftus R, Elmariah SB, Ralston J, Kamino H, Franks AG. Hypertrophic discoid lupus erythematosus. Dermatology online journal 2010. link 9 Rose RF, Merchant W, Goulden V. Retroauricular milia en plaque: a rare presentation of lupus erythematosus. Clinical and experimental dermatology 2008. link 10 Ahmed F, Kelsey PR, Shariff N. Lupus syndrome with neutropenia following minocycline therapy - a case report. International journal of laboratory hematology 2008. link 11 Badeloe S, Henquet CJ, Nieuwhof CM, Frank J. Secondary erythromelalgia involving the ears probably preceding lupus erythematosus. International journal of dermatology 2007. link 12 Fatovic-Ferencic S, Holubar K. Early history and iconography of lupus erythematosus. Clinics in dermatology 2004. link 13 Holubar K, Fatović-Ferencić S. Cazenave, Kaposi and lupus erythematosus. A centennial and a sesquicentennial. Dermatology (Basel, Switzerland) 2001. link 14 Crosson J, Stillman MT. Minocycline-related lupus erythematosus with associated liver disease. Journal of the American Academy of Dermatology 1997. link70043-4) 15 Gordon PM, White MI, Herriot R, Martin JC, Reid DM. Minocycline-associated lupus erythematosus. The British journal of dermatology 1995. link 16 Bos JD. The skin immune system: lupus erythematosus as a paradigm. Archives of dermatological research 1994. link 17 Beutner EH, Blaszczyk M, Jablonska S, Chorzelski TP, Kumar V, Wolska H. Studies on criteria of the European Academy of Dermatology and Venerology for the classification of cutaneous lupus erythematosus. I. Selection of clinical groups and study factors. International journal of dermatology 1991. link 18 Alballa S, Fritzler M, Davis P. A case of drug induced lupus due to carbamazepine. The Journal of rheumatology 1987. link 19 Rafferty P, Young AC, Haeney MR. Sulphasalazine-induced cerebral lupus erythematosus. Postgraduate medical journal 1982. link 20 Hunyadi J, Dobozy A, Husz S, Kenderessy AS, Szegedi G, Simon N. Supressor activity of peripheral blood mononuclear cells in patients with chronic discoid lupus erythematosus. Archives of dermatological research 1979. link 21 Wrzolkowa T, Kozakiewicz J. Virus-like structures in the skin in the course of chronic lupus erythematosus. Dermatologica 1977. link 22 Stone JA, Leavell UW. Unusual cells in lupus erythematosus bullae. Archives of dermatology 1976. link

Lupus erythematosus